Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Isatuximab Affords the R/R Multiple Myeloma Setting a Tolerable New Alternative

March 31st 2020

Ken Shain, MD, PhD, discusses isatuximab-irfc and its potential to move into different stages of the multiple myeloma paradigm following further clinical investigation.

FDA Approval Sought for Idecabtagene Vicleucel in Multiple Myeloma

March 31st 2020

A biologics license application has been submitted to the FDA for idecabtagene vicleucel (ide-cel; bb2121) for the treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Dr. Munshi on Testing for MRD in Multiple Myeloma

March 21st 2020

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses ways to test for minimal residual disease (MRD) in multiple myeloma.

Dr. Kumar on Ongoing Research in Multiple Myeloma

March 21st 2020

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses ongoing research in multiple myeloma.

Dr. Hillengass on Imaging Modalities in Multiple Myeloma

March 20th 2020

Jens Hillengass, MD, discusses available imaging modalities in multiple myeloma.

Dr. Hari on Misconceptions Regarding Allogeneic Stem Cell Transplant in Multiple Myeloma

March 19th 2020

Parameswaran Hari, MD, MRCP, discusses misconceptions regarding allogeneic stem cell transplant in multiple myeloma.

The Future of Multiple Myeloma Management

March 19th 2020

The Role of Genetic Testing and Targeted Therapy

March 19th 2020

MGUS Follow-Up Recommendations

March 19th 2020

MGUS Progression Risk: Immune Marker Alterations & FLC

March 19th 2020

Clinical Significance of Available FLC Assays

March 19th 2020

MGUS Management Guidelines for Practicing Internists

March 19th 2020

The Importance of Early Diagnosis: Multiple Myeloma, MGUS & AL Amyloidosis

March 19th 2020

MGUS and Multiple Myeloma (MM) Diagnostic Criteria

March 19th 2020

The Clinical Significance of MGUS

March 19th 2020

Prevalence and Relapse of Multiple Myeloma and MGUS

March 19th 2020

Advances in Multiple Myeloma Diagnostic Work-up

March 19th 2020

Ixazomib Frontline Triplet Misses PFS Endpoint in Transplant-Ineligible Myeloma

March 10th 2020

The triplet therapy of ixazomib, lenalidomide, and dexamethasone showed an improvement in progression-free survival, but it was not statistically significant, compared with lenalidomide/dexamethasone alone for patients with newly diagnosed multiple myeloma who were ineligible for stem cell transplant.

Novel Regimens Show Continued Improvements in Newly Diagnosed Myeloma

March 9th 2020

The frontline treatment of patients with multiple myeloma continues to evolve with novel, multidrug regimens that are leading to higher, deeper, and more durable responses, as well as increased rates of minimal residual disease negativity.

Frontline Elotuzumab Triplet Misses PFS Endpoint in Multiple Myeloma

March 9th 2020

The addition of elotuzumab to lenalidomide and dexamethasone did not show a statistically significant improvement in progression-free survival compared with lenalidomide/dexamethasone alone in patients with newly diagnosed, previously untreated, transplant-ineligible multiple myeloma.